...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of International Medical Research >Fibrinolysis is a reasonable alternative for STEMI care during the COVID-19 pandemic
【24h】

Fibrinolysis is a reasonable alternative for STEMI care during the COVID-19 pandemic

机译：纤维蛋白溶解是在Covid-19大流行期间Stemi护理的合理替代方案

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective No data are available to develop uniform recommendations for reperfusion therapies in ST-segment elevation myocardial infarction (STEMI) during the coronavirus disease 2019 (COVID-19) pandemic. We aimed to fill the evidence gap regarding STEMI reperfusion strategy during the COVID-19 era. Methods Clinical characteristics and outcomes for 17 patients with STEMI who received fibrinolysis during the COVID-19 pandemic were compared with 20 patients who received primary percutaneous coronary intervention (PPCI), and were further compared with another 41 patients who received PPCI in the pre-COVID-19 period. Results In patients with STEMI, fibrinolysis achieved a comparable in-hospital and 30-day primary composite end point, as compared with those who received PPCI during the COVID-19 pandemic. No major bleeding was detected in either group. Compared patients with STEMI who received PPCI in the pre-COVID-19 period, we found a remarkable extension of chest pain onset-to-first medical contact (FMC) and FMC-to-wire crossing times, significantly increased number and length of stents, and much worse thrombolysis in myocardial infarction flow in patients with STEMI who received PPCI during the COVID-19 pandemic. Conclusion Owing to its considerable efficacy and safety and advantages in conserving medical resources, we recommend fibrinolysis as a reasonable alternative for STEMI care during the COVID-19 pandemic.
机译：目的没有数据可以在2019年冠状病毒疾病（Covid-19）大流行期间制定用于ST段抬高心肌梗死（Stemi）的再灌注疗法的统一建议。我们的目标是在Covid-19时代期间填补关于Stemi再灌注策略的证据差距。方法对17例治疗纤维蛋白溶解的患者临床特征及结果与在Covid-19大流行期间接受纤维蛋白溶解的患者，与20名接受初步经皮冠状动脉介入（PPCI）的患者进行了比较，并与另一个在Pre-Covid中接受PPCI的另外41名患者进行比较-19期。结果患者患者，纤维蛋白溶解，与在Covid-19大流行期间接受PPCI的人相比，纤维蛋白溶解的纤维蛋白溶解于医院和30天的主要复合终点。任何一组都没有检测到重大出血。比较患有PPCI的患者在Covid-19期间接受PPCI，我们发现胸痛发作到第一医学接触（FMC）和FMC到线过桥时间，显着增加的支架数量和长度在Covid-19大流行期间接受PPCI患者心肌梗死患者中心肌梗塞流量的溶栓更差。结论由于其在保存医疗资源方面具有相当大的疗效和安全性和优势，我们建议纤维蛋白溶解作为在Covid-19大流行期间Stemi Care的合理替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号